High thrombin-activatable fibrinolysis inhibitor levels may protect against recurrent fetal loss

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 5, 2009, Pages 903-906

  Knol, H Marieke ^a   Veeger, N J G M ^a   Middeldorp, S ^b,c   Hamulyak K ^d   Van Der Meer, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; CONTROLLED STUDY; FEMALE; FETUS WASTAGE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY TERMINATION; PRIMIGRAVIDA; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ABORTION, HABITUAL; ADOLESCENT; ADULT; CARBOXYPEPTIDASE U; FEMALE; HUMANS; PREGNANCY; YOUNG ADULT;

EID: 65349091423     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03336.x     Document Type: Article

References (15)

1. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
2. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3: 2211-18.
3. Folkeringa N, Korteweg FJ, Veeger NJ, Middeldorp S, Hamulyak K, Prins MH, Erwich JJ, Buller HR, van der Meer J. Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study. Thromb Res 2009; 123: 511-14.
4. Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115: 150-2.
5. Mousa HA, Downey C, Alfirevic Z, Toh CH. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 2004; 92: 1025-31.
6. Bank I, Libourel EJ, Middeldorp S, van Pampus EC, Koopman MM, Hamulyak K, Prins MH, van der Meer J, Buller HR. Prothrombin 20210A mutation: A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 164: 1932-7.
7. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, Prins MH, van der Meer J, Buller HR. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
8. Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: Evidence for multiple interrelated causes. Ann Intern Med 2006; 145: 807-15.
9. Lijfering WM, Coppens M, van de Poel MH, Middeldorp S, Hamulyak K, Bank I, Veeger NJ, Prins MH, Buller HR, van der Meer J. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-63.
10. Stirrat GM. Recurrent miscarriage. Lancet 1990; 336: 673-5.
11. Masini S, Ticconi C, Gravina P, Tomassini M, Pietropolli A, Forte V, Federici G, Piccione E, Bernardini S. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss. Fertil Steril 2008, doi: 10.1016/j.fertnstert.2008.07.015.
12. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 9: 331-7.
13. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-16.
14. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K, Prins MH, Buller HR, van der Meer J. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999; 130: 736-9.
15. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-8.